BCAX Bicara Therapeutics Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why BCAX matters now
Bicara Therapeutics Inc. Common Stock (BCAX) is a US stock in Healthcare. The latest InvestLog snapshot shows $28.91 with -2.59% on the session and $1.58B in market capitalization; recent performance reads 1-month +15.98% and YTD +38.03%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-56.2M, and EPS of $-0.93. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.2%.
The latest indexable market news headline is "Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $32.50; recent insider activity includes Simson Jake filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.74
P/S
0.00
EV/EBITDA
-6.05
DCF Value
$1.64
FCF Yield
-9.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.9%
ROA
-28.4%
ROIC
-33.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-56.2M | $-0.93 |
| Q4 2025 | $0.00 | $-37.4M | $-0.68 |
| FY 2025 | $0.00 | $-137.9M | $-2.52 |
| Q3 2025 | $0.00 | $-36.3M | $-0.67 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$31.25
Target (Median)
$32.50
Target Range
$18.00 - $42.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.53
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.